Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostly ACTH deficiency, which is usually permanent. We describe a series of 3 cases developing pituitary enlargement in keeping with hypophysitis after ipilimumab without any long-term pituitary hormone deficiencies. This illustrates that a comprehensive endocrine assessment is required even when pituitary enlargement is present.

中文翻译：

---

无长期内分泌功能障碍的易普利姆玛后垂体增大

Ipilimumab 是一种针对 CTLA-4 的单克隆抗体，用于治疗黑色素瘤和肾细胞癌。垂体炎是较常见的不良事件之一，通常表现为头痛、垂体增大和垂体功能减退，多为 ACTH 缺乏，通常是永久性的。我们描述了一系列 3 例在 ipilimumab 后发生垂体增大与垂体炎一致且没有任何长期垂体激素缺乏的病例。这说明即使存在垂体增大，也需要进行全面的内分泌评估。